/

JAGX

Jaguar Health, Inc.Closed

4.16−0.48 −10.34%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 4.20 +0.88%

Open

4.35

Prev close

4.64

Day range

4.074.41

52-week range

2.351,260.00

Volume

431.19K0.21×

Mkt cap

8.09M

P/E ttm

—

Fwd P/E

-0.73

EPS ttm

-4,012.65

Div yield

0.00%

Earnings

Aug 19, 2026

From 52w high

−99.67%

Price Chart

Yahoo Finance · delayed

JAGXOct 13, 2026O 4.35H 4.41L 4.07C 4.16−0.48 (−10.34%)Vol 434.70K

SMA 509.28
SMA 200153.28

1Y change −99.63% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

JAGX Jaguar Health, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −25.98%
1 month: −11.68%
3 months: −87.22%
6 months: −98.05%
Year to date: −99.15%
1 year: −99.63%

Valuation & ownership

Market cap: 8.09M
Enterprise value: 14.26M
P/E (ttm): —
Forward P/E: -0.73
PEG ratio: —
Price / book: 0.20
Price / sales (ttm): 0.29
EV / EBITDA: -0.61
EPS (ttm): -4,012.65
EPS (forward): -5.68
Beta (5y monthly): -0.10
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 1.95M
Float: 289.42K
Short % of float: 4.33%
Short ratio (days): 0.02
Held by insiders: 4.38%
Held by institutions: 1.77%
Avg volume (3m): 2.06M
50-day average: 9.49
200-day average: 156.22
52-week change: −99.63%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 44.7
vs 50-day SMA: −55.15%
vs 200-day SMA: −97.29%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 69.18%
Realised vol (20d, ann.): 1077.4%
From 52-week high: −99.67%
From 52-week low: +77.02%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 27.82M
Revenue growth (yoy): −58.90%
Earnings growth (yoy): —
Gross margin: 82.31%
Operating margin: -620.16%
Profit margin: -130.85%

DES

About Jaguar Health, Inc.

Yahoo Finance profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 47
Headquarters: San Francisco, CA, United States
Website: jaguar.health
Officers: Ms. Lisa A. Conte

SEAS

Seasonality · JAGX

2015–2026 · monthly returns

Strongest month Jan +20.18%Weakest month Feb −24.28%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-27.5	31.6	-58.2	-46.4	-49.0	-15.5	-66.7	-20.9	-62.1	-7.6			−99.1%
2025	-12.5	-30.2	-69.1	157.1	-64.1	-42.7	-19.0	-20.1	42.9	-16.7	-30.4	-31.0	−96.3%
2024	-31.1	-43.3	52.5	138.9	-67.3	-15.2	-65.6	-7.3	18.4	-22.2	-1.0	-2.9	−88.9%
2023	-30.6	-57.6	-67.3	-20.5	33.1	-22.3	25.8	-40.7	-32.5	33.1	2.3	-57.3	−97.7%
2022	-21.7	-44.0	55.5	-36.8	-18.8	-19.2	-12.6	-8.6	-33.6	-10.3	-7.1	-33.1	−91.6%
2021	246.0	-25.5	-14.3	-16.1	6.0	-1.2	-11.4	-14.3	-36.9	-6.2	-38.5	-20.6	−57.5%
2020	-4.1	-25.8	-15.8	-5.0	5.9	0.4	34.8	-38.8	-27.5	-31.4	75.9	132.9	+1.7%
2019	11.4	-32.2	61.8	-18.2	-27.9	-59.3	-63.4	-32.6	12.9	-43.5	-17.6	31.3	−95.0%
2018	-9.3	16.5	31.8	-11.8	-22.1	-29.4	-28.2	-17.5	2.7	-50.1	4.2	-49.1	−89.1%
2017	15.9	43.4	-16.0	-14.4	-22.9	-19.7	5.7	-33.4	-46.4	-9.0	-14.3	-10.3	−80.4%
2016	37.8	-44.2	-8.7	7.6	-17.6	31.4	-5.4	-25.3	-1.5	-26.6	-28.6	6.7	−68.2%
2015						-28.4	-26.1	-19.4	12.9	13.6	-40.5	2.7	−66.6%

INSD

Insider Activity · JAGX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.97M shares

Sells, 6 months

326.1K shares

Net shares

+1.65M

Net change in insider shares

−100.90%

Date	Insider	Transaction	Shares	Value
Dec 10, 2025	Bochnowski James J.Director	—	6.4K	—
Dec 10, 2025	Micek John J IiiDirector	—	7.4K	—
Dec 10, 2025	King Steven R. Ph.D.Officer	—	11.7K	—
Dec 10, 2025	Conte Lisa A.Chief Executive Officer	—	28.6K	—
Dec 10, 2025	Siegel Jonathan BDirector	—	7.4K	—
Dec 10, 2025	Lizak Carol R.Chief Financial Officer	—	11.7K	—
Dec 10, 2025	Wolin Jonathan SGeneral Counsel	—	11.7K	—
Dec 10, 2025	Jayasuriya AnulaDirector	—	5.9K	—
Dec 10, 2025	Chaturvedi Pravin ROfficer	—	11.7K	—
May 15, 2025	King Steven R. Ph.D.Officer	—	1	—
May 15, 2025	Conte Lisa A.Chief Executive Officer	—	2	—
Oct 7, 2024	King Steven R. Ph.D.Officer	—	4.9K	—
Oct 7, 2024	Conte Lisa A.Chief Executive Officer	—	16.5K	—
Oct 7, 2024	Lizak Carol R.Chief Financial Officer	—	4.3K	—
Oct 7, 2024	Wolin Jonathan SGeneral Counsel	—	4.9K	—
Oct 7, 2024	Chaturvedi Pravin ROfficer	—	4.9K	—

JAGX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

JAGX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Jaguar Health, Inc.

Seasonality · JAGX

Insider Activity · JAGX

Congress Trades · JAGX

Investors Holding JAGX

Investors Holding JAGX

Congress Trades · JAGX

Insider Activity · JAGX

Seasonality · JAGX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Jaguar Health, Inc.

Earnings & Dividends

News